As U.S. Takes Aim at China Drug Makers, Innovators Appear at Biggest Risk
Washington’s campaign to keep cutting-edge technology out of China took a new twist late last week with the addition of Chinese medical companies to U.S. blacklists Key takeaways: Washington has…
RELATED ARTICLES
-
I-Mab gets new CEO after long search. Sale of the company coming next?
IMAB.US
-
Heated market for dueling blood cancer drugs lands BeiGene in court
BGNE.US 6160.HK
-
Sales success comes with side effects for drug maker BeiGene
BGNE.US 6160.HK
-
BeiGene goes for global growth with sales and R&D push
BGNE.US 6160.HK
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
-
RemeGen hopes for pain relief from expanded drug uses
9995.HK 688331.SHG
Discover hidden China stock gems in our weekly newsletter